Post Traumatic Stress Disorder Clinical Trial
— CBCTOfficial title:
An Integrative Technology Approach to Home-based Conjoint Therapy for PTSD
Verified date | December 2021 |
Source | VA Office of Research and Development |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Untreated posttraumatic stress disorder (PTSD) is a costly condition associated with impairment in functioning across a host of psychosocial domains including occupational and academic functioning, marital and family functioning, parenting, and socialization. Impairment is not limited to Veterans with PTSD because the entire family is affected, particularly the Veteran's intimate partner. PTSD symptoms can produce negative effects on both members of the dyad. Despite the need for treatment, many Veterans and their families do not access PTSD-related services due to a number of barriers to accessing care (e.g., living in rural or remote areas where no specialty services exist, concerns about stigma around using mental health services, limited clinic hours to accommodate patient schedules). The objective of this study is to assess whether providing Cognitive-Behavioral Conjoint Therapy, in which PTSD symptoms and intimate relationship functioning are addressed, to Veterans and their romantic partners in their homes via clinical video teleconferencing leads to better outcomes compared to office based treatment.
Status | Completed |
Enrollment | 274 |
Est. completion date | March 31, 2021 |
Est. primary completion date | September 30, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Be a Veteran (age 18 or older) with a current Diagnostic and Statistical Manual-5 (DSM-5) diagnosis of PTSD (as assessed by the CAPS) no less than 3 months after the index trauma occurred (to allow for potential natural recovery) - Be on a stable psychoactive medication regimen for at least 2 months (if eligible) - Be an intimate partner (age 18 or older) who is willing to participate in the intervention. - Be randomized into any of the three treatment conditions - Have assessment and treatment sessions audio recorded - Agree not to receive other individual or conjoint psychotherapy for PTSD during the treatment portion of the study - Consistent with home-based clinical trials and actual clinical practice - Participants enrolled into the study will need to have access to internet via Digital Subscriber Line (DSL) or a cable provider in case they are randomized into the home-based condition. - The frequency of occurrence of no internet service will be tracked - If the PTSD-positive Veteran is currently receiving treatment at the VA, study staff will consult with their primary clinician prior to their inclusion in the study Exclusion Criteria: - Current substance dependence in either member of the couple not in remission for at least 3 months, as assessed by the Alcohol Use Disorders Identification Test (AUDIT)108 and Drug Abuse Screening Test (DAST) - Any current uncontrolled psychotic disorder in either member of the couple - Imminent suicidality or homicidality in either member of the couple - Any severe cognitive impairment in either member of the couple - Any perpetration of severe physical or sexual relationship aggression in the past year (as assessed by the Conflict Tactics Scale-2 [CTS-2]). - Participants who do not meet study criteria will be offered referrals to alternate services, as well as assistance in contacting the referral sites as needed |
Country | Name | City | State |
---|---|---|---|
United States | VA San Diego Healthcare System, San Diego, CA | San Diego | California |
Lead Sponsor | Collaborator |
---|---|
VA Office of Research and Development |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clinician Administered PTSD Scale (CAPS) | The CAPS-5 is a 30-item clinician administered interview designed to diagnose current and lifetime PTSD and to assess PTSD symptom-severity over the past week. The interview assesses 20 DSM-5 PTSD symptoms as well as onset, duration, distress, and functional impact, overall validity, PTSD severity, and presence of dissociation. Prior to assessing symptoms, the clinical interviewer works with the patient to establish an index-trauma and each follow-up question focuses on symptoms as they relate to the index trauma.
*Score range: 0-80 with higher score indicating greater symptom severity |
Baseline | |
Primary | Clinician Administered PTSD Scale (CAPS) | The CAPS-5 is a 30-item clinician administered interview designed to diagnose current and lifetime PTSD and to assess PTSD symptom-severity over the past week. The interview assesses 20 DSM-5 PTSD symptoms as well as onset, duration, distress, and functional impact, overall validity, PTSD severity, and presence of dissociation. Prior to assessing symptoms, the clinical interviewer works with the patient to establish an index-trauma and each follow-up question focuses on symptoms as they relate to the index trauma.
*Score range: 0-80 with higher score indicating greater symptom severity |
1 Month Post Treatment | |
Primary | Clinician Administered PTSD Scale (CAPS) | The CAPS-5 is a 30-item clinician administered interview designed to diagnose current and lifetime PTSD and to assess PTSD symptom-severity over the past week. The interview assesses 20 DSM-5 PTSD symptoms as well as onset, duration, distress, and functional impact, overall validity, PTSD severity, and presence of dissociation. Prior to assessing symptoms, the clinical interviewer works with the patient to establish an index-trauma and each follow-up question focuses on symptoms as they relate to the index trauma.
*Score range: 0-80 with higher score indicating greater symptom severity |
3-Months Post Treatment | |
Primary | Clinician Administered PTSD Scale (CAPS) | The CAPS-5 is a 30-item clinician administered interview designed to diagnose current and lifetime PTSD and to assess PTSD symptom-severity over the past week. The interview assesses 20 DSM-5 PTSD symptoms as well as onset, duration, distress, and functional impact, overall validity, PTSD severity, and presence of dissociation. Prior to assessing symptoms, the clinical interviewer works with the patient to establish an index-trauma and each follow-up question focuses on symptoms as they relate to the index trauma.
*Score range: 0-80 with higher score indicating greater symptom severity |
6- Months Post Treatment | |
Primary | Couples Satisfaction Index (CSI) | The Couples Satisfaction Index is a 32-item self-report survey assessing several domains of relationship satisfaction. Higher sum scores (range 0 to 161) represent higher relationship satisfaction. | Baseline | |
Primary | Couples Satisfaction Index (CSI) | The Couples Satisfaction Index is a 32-item self-report survey assessing several domains of relationship satisfaction. Higher sum scores (range 0 to 161) represent higher relationship satisfaction. | Mid Treatment (Approximately week 5 of all treatment conditions) | |
Primary | Couples Satisfaction Index (CSI) | The Couples Satisfaction Index is a 32-item self-report survey assessing several domains of relationship satisfaction. Higher sum scores (range 0 to 161) represent higher relationship satisfaction. | 1 Month Post Treatment | |
Primary | Couples Satisfaction Index (CSI) | The Couples Satisfaction Index is a 32-item self-report survey assessing several domains of relationship satisfaction. Higher sum scores (range 0 to 161) represent higher relationship satisfaction. | 3- Months Post Treatment | |
Primary | Couples Satisfaction Index (CSI) | The Couples Satisfaction Index is a 32-item self-report survey assessing several domains of relationship satisfaction. Higher sum scores (range 0 to 161) represent higher relationship satisfaction. | 6- Months Post Treatment | |
Primary | Inventory of Psychosocial Functioning (IPF) | The Inventory of Psychosocial Functioning (IPF) is an 80-item self-report measure designed to assess multiple dimensions of functional impairment related to psychiatric disturbances. Higher sum scores (range 0 to 100) indicate more functional impairment. | Baseline | |
Primary | Inventory of Psychosocial Functioning (IPF) | The Inventory of Psychosocial Functioning (IPF) is an 80-item self-report measure designed to assess multiple dimensions of functional impairment related to psychiatric disturbances. Higher sum scores (range 0 to 100) indicate more functional impairment. | Mid Treatment (Approximately week 5 of all treatment conditions) | |
Primary | Inventory of Psychosocial Functioning (IPF) | The Inventory of Psychosocial Functioning (IPF) is an 80-item self-report measure designed to assess multiple dimensions of functional impairment related to psychiatric disturbances. Higher sum scores (range 0 to 100) indicate more functional impairment. | 1 Month Post Treatment | |
Primary | Inventory of Psychosocial Functioning (IPF) | The Inventory of Psychosocial Functioning (IPF) is an 80-item self-report measure designed to assess multiple dimensions of functional impairment related to psychiatric disturbances. Higher sum scores (range 0 to 100) indicate more functional impairment. | 3- Months Post Treatment | |
Primary | Inventory of Psychosocial Functioning (IPF) | The Inventory of Psychosocial Functioning (IPF) is an 80-item self-report measure designed to assess multiple dimensions of functional impairment related to psychiatric disturbances. Higher sum scores (range 0 to 100) indicate more functional impairment. | 6- Months Post Treatment | |
Primary | Client Satisfaction Questionnaire (CSQ) | Client Satisfaction Questionnaire (CSQ) is an 8-item measure about satisfaction with treatment rated on a 4-point Likert scale. Higher mean scores (range 0 to 4) represent higher satisfaction with treatment services. | 1 Month Post Treatment | |
Primary | Working Alliance Inventory- Short Form (WAI-S) | This adaptation of the Working Alliance Inventory- short form (WAI-S) includes 14 items assessing therapeutic alliance as reported by the patient on a 7-point Likert scale. Higher sum scores (14 to 98) represent higher patient-reported working alliance. | Approximately week 3 of all treatment conditions | |
Primary | Working Alliance Inventory- Short Form (WAI-S) | This adaptation of the Working Alliance Inventory- short form (WAI-S) includes 14 items assessing therapeutic alliance as reported by the patient on a 7-point Likert scale. Higher sum scores (14 to 98) represent higher patient-reported working alliance. | Approximately week 8 of all treatment conditions | |
Secondary | PTSD Checklist-5 (PCL-5) | The PCL-5 is a 20 item self report questionnaire assessing symptoms of PTSD based on DSM-V criteria. Scores range from 0 to 80, with higher scores representing more severe symptoms. | Baseline | |
Secondary | PTSD Checklist-5 (PCL-5) | The PCL-5 is a 20 item self report questionnaire assessing symptoms of PTSD based on DSM-V criteria. Scores range from 0 to 80, with higher scores representing more severe symptoms. | Mid Treatment (Approximately week 5 of all treatment conditions) | |
Secondary | PTSD Checklist-5 (PCL-5) | The PCL-5 is a 20 item self report questionnaire assessing symptoms of PTSD based on DSM-V criteria. Scores range from 0 to 80, with higher scores representing more severe symptoms. | 1 Month Post Treatment | |
Secondary | PTSD Checklist-5 (PCL-5) | The PCL-5 is a 20 item self report questionnaire assessing symptoms of PTSD based on DSM-V criteria. Scores range from 0 to 80, with higher scores representing more severe symptoms. | 3- Months Post Treatment | |
Secondary | PTSD Checklist-5 (PCL-5) | The PCL-5 is a 20 item self report questionnaire assessing symptoms of PTSD based on DSM-V criteria. Scores range from 0 to 80, with higher scores representing more severe symptoms. | 6-Months Post Treatment | |
Secondary | Beck Depression Inventory-II (BDI-2) | The BDI is a 21-item self report questionnaire assessing symptoms of depression. Scores range from 0 to 63, with higher scores representing more severe symptoms. | Baseline | |
Secondary | Beck Depression Inventory-II (BDI-2) | The BDI is a 21-item self report questionnaire assessing symptoms of depression. Scores range from 0 to 63, with higher scores representing more severe symptoms. | Mid Treatment (Approximately Week 5 of all treatment conditions) | |
Secondary | Beck Depression Inventory-II (BDI-2) | The BDI is a 21-item self report questionnaire assessing symptoms of depression. Scores range from 0 to 63, with higher scores representing more severe symptoms. | 1 Month Post Treatment | |
Secondary | Beck Depression Inventory-II (BDI-2) | The BDI is a 21-item self report questionnaire assessing symptoms of depression. Scores range from 0 to 63, with higher scores representing more severe symptoms. | 3- Months Post Treatment | |
Secondary | Beck Depression Inventory-II (BDI-2) | The BDI is a 21-item self report questionnaire assessing symptoms of depression. Scores range from 0 to 63, with higher scores representing more severe symptoms. | 6-Months Post Treatment | |
Secondary | State-Trait Anger Inventory (STAXI) | The STAXI-2 is a self-report questionnaire assessing state and trait anger. The State subscale (15 items) ranges from 15 to 60, and the Trait subscale (10 items) ranges from 10 to 40, with higher scores representing more anger. | Baseline | |
Secondary | State-Trait Anger Inventory (STAXI) | The STAXI-2 is a self-report questionnaire assessing state and trait anger. The State subscale (15 items) ranges from 15 to 60, and the Trait subscale (10 items) ranges from 10 to 40, with higher scores representing more anger. | Mid Treatment (Approximately week 5 of all treatment conditions) | |
Secondary | State-Trait Anger Inventory (STAXI) | The STAXI-2 is a self-report questionnaire assessing state and trait anger. The State subscale (15 items) ranges from 15 to 60, and the Trait subscale (10 items) ranges from 10 to 40, with higher scores representing more anger. | 1 Month Post Treatment | |
Secondary | State-Trait Anger Inventory (STAXI) | The STAXI-2 is a self-report questionnaire assessing state and trait anger. The State subscale (15 items) ranges from 15 to 60, and the Trait subscale (10 items) ranges from 10 to 40, with higher scores representing more anger. | 3- Months Post Treatment | |
Secondary | State-Trait Anger Inventory (STAXI) | The STAXI-2 is a self-report questionnaire assessing state and trait anger. The State subscale (15 items) ranges from 15 to 60, and the Trait subscale (10 items) ranges from 10 to 40, with higher scores representing more anger. | 6-Months Post Treatment | |
Secondary | Conflict Tactics Scale Short Form- (CTS-2S) | 20-item self-report inventory yielding 5 scales. Most widely used measure of its kind. Scores on the Psychological Aggression and Negotiation subscales range from 0 to 24, with higher scores representing more Psychological Aggression and more Negotiation. | Baseline | |
Secondary | Conflict Tactics Scale Short Form- (CTS-2S) | 20-item self-report inventory yielding 5 scales. Most widely used measure of its kind. Scores on the Psychological Aggression and Negotiation subscales range from 0 to 24, with higher scores representing more Psychological Aggression and more Negotiation. | Mid Treatment (Approximately week 5 of all treatment conditions) | |
Secondary | Conflict Tactics Scale Short Form- (CTS-2S) | 20-item self-report inventory yielding 5 scales. Most widely used measure of its kind. Scores on the Psychological Aggression and Negotiation subscales range from 0 to 24, with higher scores representing more Psychological Aggression and more Negotiation. | 1 Month Post Treatment | |
Secondary | Conflict Tactics Scale Short Form- (CTS-2S) | 20-item self-report inventory yielding 5 scales. Most widely used measure of its kind. Scores on the Psychological Aggression and Negotiation subscales range from 0 to 24, with higher scores representing more Psychological Aggression and more Negotiation. | 3- Months Post Treatment | |
Secondary | Conflict Tactics Scale Short Form- (CTS-2S) | 20-item self-report inventory yielding 5 scales. Most widely used measure of its kind. Scores on the Psychological Aggression and Negotiation subscales range from 0 to 24, with higher scores representing more Psychological Aggression and more Negotiation. | 6-Months Post Treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05915013 -
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
|
Phase 1 | |
Recruiting |
NCT05563805 -
Exploring Virtual Reality Adventure Training Exergaming
|
N/A | |
Recruiting |
NCT05934175 -
Intensive Treatment Versus Standard Weekly Prolonged Exposure for Adults With Post-Traumatic Stress Disorder
|
N/A | |
Recruiting |
NCT05934162 -
Efficacy of Internet-delivered Cognitive-behavior Therapy for PTSD
|
N/A | |
Completed |
NCT04460014 -
Simple Cognitive Task Intervention After Trauma During COVID-19 In Hospital Staff EKUT-P RCT
|
N/A | |
Completed |
NCT05877807 -
Effect of Baclofen to Prevent Post-Traumatic Stress Disorder
|
||
Active, not recruiting |
NCT05992649 -
The Effect of Aquatic Physiotherapy on Veterans Suffering From PTSD - a 40-week Pilotproject
|
N/A | |
Terminated |
NCT04404712 -
FAAH Availability in Psychiatric Disorders: A PET Study
|
Early Phase 1 | |
Not yet recruiting |
NCT05331534 -
Effect of Attentional Therapy on Post-traumatic Stress Disorder
|
N/A | |
Not yet recruiting |
NCT04076215 -
Biochemical and Physiological Response to Stressogenic Stimuli
|
N/A | |
Not yet recruiting |
NCT03649607 -
Accelerated Resolution Therapy for HIV Positive African, Caribbean and Black
|
N/A | |
Not yet recruiting |
NCT02545192 -
A Pilot Study of Low Field Magnetic Stimulation in PTSD: Three Daily Treatments
|
Phase 1 | |
Completed |
NCT02329418 -
Written Document to Assist Family During Decision of Withholding and Withdrawing Life-sustaining Therapies in the Intensive Care Unit
|
N/A | |
Active, not recruiting |
NCT00978484 -
A Head-to-head Comparison of Virtual Reality Treatment for Post Traumatic Stress Disorder
|
Phase 3 | |
Completed |
NCT00760734 -
Hyperbaric Oxygen Therapy (HBOT) in Chronic Traumatic Brain Injury (TBI)/Post Concussion Syndrome (PCS) and TBI/Post-Traumatic Stress Disorder (PTSD)
|
Phase 1 | |
Completed |
NCT03278171 -
Early Detection of Patients at Risk of Developing a Post-traumatic Stress Disorder After a Stay in Intensive Care Unit
|
||
Recruiting |
NCT05874362 -
People Bereaved by Violent Death : Negative Event Biases and Temporal Perception
|
N/A | |
Terminated |
NCT03898843 -
Assisted Animal Therapy: ReAnimal
|
N/A | |
Recruiting |
NCT04747379 -
Psychological Effect of Explicit Recall After Sedation (PEERS)
|
||
Completed |
NCT03248167 -
Cannabidiol as a Treatment for AUD Comorbid With PTSD
|
Phase 1/Phase 2 |